Onfekafusp alfa

DRUG4 trials

Sponsors

Philogen S.p.A.

Conditions

GlioblastomaSoft Tissue Sarcoma

Phase 1

Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma

RecruitingNCT04443010

Philogen S.p.A.Glioblastoma

Start: 2021-01-20End: 2026-12-31Target: 226Updated: 2023-10-10

Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression

WithdrawnNCT05304663

Philogen S.p.A.Glioblastoma

Start: 2022-06-01End: 2024-12-31Updated: 2024-04-08

Phase 2

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Active, not recruitingNCT04733183

Philogen S.p.A.Soft Tissue Sarcoma

Start: 2020-08-28End: 2025-12-31Target: 98Updated: 2025-01-27

Phase 3

A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

RecruitingNCT04650984

Philogen S.p.A.Soft Tissue Sarcoma

Start: 2017-11-29End: 2025-12-31Target: 102Updated: 2024-04-08

Related Papers

KS04.7.A L19TNF IN COMBINATION WITH TEMOZOLOMIDE-BASED CHEMORADIATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA SHOWS PROMISING SAFETY AND OVERALL SURVIVAL SIGNALS IN A PHASE I STUDY

Neuro-Oncology2025-10-01

P06.08.A CLINICAL OUTCOME AND TRANSLATIONAL INSIGHTS FROM A PHASE I/II TRIAL WITH THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF FOR PATIENTS WITH RECURRENT GLIOBLASTOMA

Neuro-Oncology2023-09-011 citations